Protecting the Cold Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Protecting the Cold Chain
Makers of temperature-sensitive products constantly seek to ensure proper conditions during shipping and storage.


Pharmaceutical Technology



Hallie Forcinio
Drugmakers have an ever-increasing array of protective materials and devices to monitor conditions and maintain sensitive products at the appropriate temperatures. The ideal innovation combines high efficiency with low cost. Options include time and temperature indicators, data loggers, and insulated packaging and refrigerants.

Indicator labels

Indicator devices, primarily labels, reveal the passage of time, temperature excursions beyond acceptable limits, or both. Many of these devices have been designed for the food industry but have potential applications in the pharmaceutical supply chain.

One temperature indicator designed to protect red blood cells is attached to the blood bag with a handheld activator. After preconditioning, activation, and application, phase-change material in the label irreversibly turns from white to red if the temperature of the contents exceeds a preset threshold ("Check-Spot" label with "Spot-Gun" handheld activator, Harald H. Temmel KEG, Gleisdorf, Austria).


As time passes, a spot of color on the "Timestrip" label darkens to show how much shelf life remains.
For products that can't be frozen, a freeze indicator provides assurance that no accidental freezing events occurred ("iStrip," Timestrip plc, Miami, FL).

Some labels monitor time rather than temperature. One technology that can be supplied as an external label or integrated into the packaging is particularly useful for products such as eyedrops, which must be used within a specific time frame. When activated, an edible oil travels across the label at a consistent rate and provides a visible indicator of how long the product has been open or in use ("Timestrip" label, Timestrip plc).

Another time-tracking option is a small, battery-equipped digital counter with a magnetic or suction-cup backing for easy mounting ("Days Ago" digital day counter, double u products, Inc., Cupertino, CA).

An indicator that registers both time and temperature consists of a clear pressure-sensitive label with a coating of food-grade microorganisms that simulate the degradation of the product. When the label is activated and applied over the barcode of the product, it slowly changes color as time passes or temperatures exceed its threshold. When the label becomes so opaque that the barcode is unreadable, the product is no longer safe to use ("Traceo" label, Cryolog, Gentilly, France).

For storage facilities, monitoring systems can provide alerts if temperatures warm or chill too much or the power fails. Light-emitting diodes on a sealed, weatherproof, lockable enclosure display alarm and status conditions for at-a-glance monitoring. Capable of measuring temperatures as low as –85 C, the monitoring system automatically calls as many as eight numbers when a problem occurs. The unit also can trip an on-premises warning device ("Sensaphone 1400" and "Sensaphone 1800," Sensaphone, Inc., Aston, PA).

Data loggers and RFID

For cold-chain applications, data loggers help ensure products remain within storage parameters during shipment by providing a record of the conditions experienced. Some of today's units are low-cost enough to be used for a single trip and often incorporate radio-frequency identification (RFID) technology to automate data transmission.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here